Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes

International Journal of Prisoner Health

Volumn 1, Issue 1, 2005, Pages 13-18

  Farley, John ^a,b   Vasdev, Shawn ^c   Fischer, Benedikt ^d   Rehm, Jürgen ^d   Haydon, Emma ^d  

^a Dr John Farley Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canadian correctional populations; HCV; Treatment

Indexed keywords

EID: 33746290806     PISSN: 17449200     EISSN: 17449219     Source Type: Journal    
DOI: 10.1080/17449200500157044     Document Type: Article

References (25)

1. Allen, S., Spaulding, A., Osei, A., Taylor, L., Cabral, A., & Rich, J. (2003). Treatment of chronic hepatitis C in a state correctional facility. Annals of Internal Medicine, 138, 187-191. (Pubitemid 36236128)
2. Backmund, M. (2002). Interferon therapy and detoxification treatment. Suchttherapie, 3, S67-S71.
3. Backmund, M., Meyer, K., von Zielonka, M., & Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34, 188-193. (Pubitemid 32591499)
4. Canadian Centre on Substance Abuse. (2004). Substance abuse in corrections (FAQ). Ottawa: CCSA.
5. Correctional Service of Canada (2003). Infectious diseases prevention and control. Ottawa: Correctional Service of Canada.
6. Davis, G. L.,Wong, J., McHutchison, J. G., Manns, M., Harvey, J., & Albrecht, J. (2003). Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patietns with chronic hepatitis C. Hepatology, 38, 645-652. (Pubitemid 37052151)
7. Di Ruggiero, E., Frank, J., & Moloughney, B. (2004). A health care needs assessment of federal inmates in Canada. Canadian Journal of Public Health, 95 (suppl. 1).
8. Dufour, A., Alary, M., Poulin, C., Allard, F., Noël, L., Trottier, G., et al. (1996). Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City. AIDS, 10, 1009-1015. (Pubitemid 26252632)
9. Fischer, B., Haydon, E., Rehm, J., Krajden, M., & Reimer, J. (2004). Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach -/The case study of Canada. Journal of Urban Health, 81, 428-447. (Pubitemid 39128279)
10. Ford, P., Pearson, M., Sankar-Mistry, P., Stevenson, T., Bell, D., & Austin, J. (2000). HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Quarterly Journal of Medicine, 93, 113-119. (Pubitemid 30098774)
11. Fried, M., Shiffman, M., Reddy, K., Smith, C., Marinos, G., Goncales, F., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975-982.
12. Hammett, T. (2003). Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Annals of Internal Medicine, 138, 235-236.
13. Hendrick, D., & Farmer, L. (2002). Adult correctional services in Canada, 2000/01. Juristat, 22, 1-24.
14. Lines, R., Jürgens, R., Betteridge, G., Stöver, H., Laticevschi, D., & Nelles, J. (2004). Prison needle exchange: Lessons from a comprehensive review of international evidence and experience. Montreal: Canadian HIV/AIDS Legal Network.
15. Macalino, G., Hou, J., Kumar, M., Taylor, L., Sumantera, I., & Rich, J. (2004). Hepatitis C and incarcerated populations. International Journal of Drug Policy, 15, 103-114.
16. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358, 958-965. (Pubitemid 32913521)
17. Remis, R. (2004). A study to characterize the epidemiology of hepatitis C infection in Canada, 2002. Final report. Ottawa: Health Canada.
18. Romanowski, B., Preiksaitis, J., Campbell, P., & Fenton, J. (2003). Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics. Sexually Transmitted Diseases, 30, 33-38. (Pubitemid 36071083)
19. Schroeder, J. R., Latkin, C. A., Hoover, D. R., Curry, A. D., Knowlton, A. R., & Celetano, D. D. (2001). Illicit drug use in one's social network and in one's neighborhood predicts individual heroin and cocaine use. Annals of Epidemiology, 11, 389-394.
20. Sherman, M., Bain, V., Villeneuve, J-P., Myers, R., Cooper, C., Martin, S., et al. (2004). Management of viral hepatitis: A Canadian consensus conference. Toronto: Canadian Association for the Study of the Liver.
21. Sherman, M., & CASL Hepatitis Consensus Group (1997). Management of viral hepatitis: clinical and public health perspectives - a consensus statement. Canadian Journal of Gastroenterology, 11, 406-417.
22. Siebert, U., Sroczynski, G., Rossol, S., Wasem, J., Ravens-Sieberer, U., Kurth, B. et al. & German Hepatitis C Model (GEHMO) Group International Hepatitis Interventioal Therapy (IHIT) Group (2003). Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut, 52, 425-432.
23. Sterling, R., Hofmann, C., Luketic, V., Sanyal, A., Contos, M., Mills, S., et al. (2004). Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: Can compliance overcome racial differences to response? American Journal of Gastroenterology, 99, 866-871.
24. Sylvestre, D. L. (2002). Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug & Alcohol Dependence, 67, 117-123.
25. Zou, S., Forrester, L., & Giulivi, A. (2003). Hepatitis C update. Canadian Journal of Public Health, 94, 127-129.